IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
US-0569805
(2005-06-01)
|
| 등록번호 |
US-8211887
(2012-07-03)
|
| 국제출원번호 |
PCT/US2005/019276
(2005-06-01)
|
| §371/§102 date |
20061130
(20061130)
|
| 국제공개번호 |
WO2005/120407
(2005-12-22)
|
|
발명자
/ 주소 |
- Richlin, David M.
- Doherty, George R.
|
| 출원인 / 주소 |
|
| 대리인 / 주소 |
|
| 인용정보 |
피인용 횟수 :
0 인용 특허 :
54 |
초록
▼
Disclosed herein is a preparation for topically delivering and localizing therapeutic agents, comprising: a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; and a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a pat
Disclosed herein is a preparation for topically delivering and localizing therapeutic agents, comprising: a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; and a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Further disclosed is an associated method of topically delivering and localizing therapeutic agents, comprising the steps of: using a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; in combination with using a penetration enhancer for facilitating penetration of the vasoconstrictor and the therapeutic agent through a patient's skin. Also disclosed are various courses of treatment, which comprise applying the various disclosed combinations of agents to the patient's skin.
대표청구항
▼
1. A preparation for topically delivering through intact skin, and localizing at least one therapeutic agent, comprising: a vasoconstrictor for retarding vascular dispersion of a therapeutic agent, said vasoconstrictor comprising phenylephrine; anda penetration enhancer for facilitating penetration
1. A preparation for topically delivering through intact skin, and localizing at least one therapeutic agent, comprising: a vasoconstrictor for retarding vascular dispersion of a therapeutic agent, said vasoconstrictor comprising phenylephrine; anda penetration enhancer for facilitating penetration of said vasoconstrictor and said therapeutic agent through a patient's skin, said penetration enhancer comprising lecithin and ethoxydiglycol; wherein:said therapeutic agent is selected from at least one therapeutic agent in at least one of the following therapeutic agent groups:(a) a local anesthetic selected from the group consisting of: levobupivacaine, ropivacaine, etidocaine, and prilocaine;(b) a quick-onset, short-acting non-steroidal anti-inflammatory agent selected from the group consisting of: ketoprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, and tolmetin;(c) a long-acting non-steroidal anti-inflammatory agent selected from the group consisting of: piroxicam, celecoxib, meloxicam, nabumetone, naproxen, oxaprozin, rofecoxib, sulindac, and valdecoxib;(d) an antiviral agent selected from the group consisting of: 2-deoxy-d-glucose, podofilox, acyclovir, penciclovir, and docosanol. 2. The preparation of claim 1, said local anesthetic further comprising bupivacaine. 3. The preparation of claim 1, said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising ketoprofen. 4. The preparation of claim 1, said long-acting non-steroidal anti-inflammatory agent comprising piroxicam. 5. The preparation of claim 1, said antiviral agent comprising 2-deoxy-d-glucose. 6. The preparation of claim 1: said local anesthetic further comprising bupivacaine;said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising ketoprofen; andsaid long-acting non-steroidal anti-inflammatory agent comprising piroxicam. 7. A method of topically delivering through intact skin, and localizing at least one therapeutic agent, comprising: topically using through intact skin, a vasoconstrictor for retarding vascular dispersion of a therapeutic agent, said vasoconstrictor comprising phenylephrine; in combination withtopically using through intact skin, a penetration enhancer for facilitating penetration of said vasoconstrictor and said therapeutic agent through a patient's skin, said penetration enhancer comprising lecithin and ethoxydiglycol; wherein:said therapeutic agent is selected from at least one therapeutic agent in at least one of the following therapeutic agent groups:(a) a local anesthetic selected from the group consisting of: levobupivacaine, ropivacaine, etidocaine, and prilocaine;(b) a quick-onset, short-acting non-steroidal anti-inflammatory agent selected from the group consisting of: ketoprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, and tolmetin;(c) a long-acting non-steroidal anti-inflammatory agent selected from the group consisting of: piroxicam, celecoxib, meloxicam, nabumetone, naproxen, oxaprozin, rofecoxib, sulindac, and valdecoxib;(d) an antiviral agent selected from the group consisting of: 2-deoxy-d-glucose, podofilox, acyclovir, penciclovir, and docosanol. 8. The method of claim 7: said using said local anesthetic further comprising using bupivacaine;said using said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising using ketoprofen; andsaid using said long-acting non-steroidal anti-inflammatory agent comprising using piroxicam. 9. The method of claim 7, said using said local anesthetic further comprising using bupivacaine. 10. The method of claim 7, said using said quick-onset, short-acting non-steroidal anti-inflammatory agent comprising using ketoprofen. 11. The method of claim 7, said using said long-acting non-steroidal anti-inflammatory agent comprising using piroxicam. 12. The method of claim 7, wherein said therapeutic agent comprising said antiviral agent comprising 2-deoxy-d-glucose.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.